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Abstract: In the face of the recent pandemic and emergence of infectious diseases of viral origin,
research on parasitic diseases such as malaria continues to remain critical and innovative methods
are required to target the rising widespread resistance that renders conventional therapies unusable.
The prolific use of auxiliary metallo-fragments has augmented the search for novel drug regimens in an
attempt to combat rising resistance. The development of organometallic compounds (those containing
metal-carbon bonds) as antimalarial drugs has been exemplified by the clinical development of
ferroquine in the nascent field of Bioorganometallic Chemistry. With their inherent physicochemical
properties, organometallic complexes can modulate the discipline of chemical biology by proffering
different modes of action and targeting various enzymes. With the beneficiation of platinum group
metals (PGMs) in mind, this review aims to describe recent studies on the antimalarial activity
of PGM-based organometallic complexes. This review does not provide an exhaustive coverage
of the literature but focusses on recent advances of bioorganometallic antimalarial drug leads,
including a brief mention of recent trends comprising interactions with biomolecules such as heme
and intracellular catalysis. This resource can be used in parallel with complementary reviews on
metal-based complexes tested against malaria.
Keywords: bioorganometallic chemistry; malaria; Plasmodium falciparum; platinum-group metals;
mechanism of action
1. Introduction
The turn of the 21st century has seen great developments and efforts directed toward containing
and eradicating the spread of infectious diseases around the globe. Drug research and innovation
within the pharmaceutical industry and academia, as well as government vaccination campaigns,
are at the forefront of these endeavours. The elimination of wildtype cases of the infectious viral
disease, polio, which has been recently declared “eradicated” from the African continent, attests to the
progress made within the field of infectious diseases [1]. Despite these successes, infectious diseases
like malaria remain prevalent and still burden the health-care sector and threaten the lives of many
in endemic regions in Sub-Saharan Africa and parts of Asia. Of the estimated 228 million cases of
malaria, in 2018, Africa was reported to have borne the largest burden, accounting for approximately
93% (213 million) of these cases [2]. Unfortunately, treatment of this disease is proving challenging,
due in part to the emergence of new, tenacious strains of the malaria parasite that are displaying
resistance to current frontline drugs used to treat this disease. Of the five Plasmodium species known
to cause malaria, Plasmodium falciparum is the most virulent, and according to the World Health
Organisation accounted for more than 400,000 deaths in 2018 alone [2]. The plight of antimalarial
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drug resistance prompted the introduction of artemisinin-based combination therapies (ACTs), which
have proven fruitful in this struggle, as this treatment regimen involves combining antimalarials with
independent modes of action to improve treatment outcomes and counter the threat of resistance [3,4].
However, reports of Plasmodium strains developing resistance to ACTs have already been recorded [5].
This demands an expansion of the antimalarial drug arsenal and search for innovative drug candidates
possessing novel mechanistic modalities unknown to the malaria parasite to combat the development
of clinical resistance.
The application of bioactive metallic compounds has been extensively explored, in contemporary
drug discovery, as nonconventional therapeutic chemotypes possessing novel, and sometimes unique
modes of action, compared with their traditional organic counterparts [6]. The success of metallodrugs
was accentuated by the seminal discovery of the platinum-based anticancer agent, cisplatin, which
has had tremendous success within cancer treatment regimens [7,8]. Concerning its pharmacological
applications, platinum is the archetype for a group of related metals, known as platinum-group
metals (PGMs), i.e., iridium, ruthenium, rhodium, osmium, platinum, and palladium, which share
many similarities in both their physical and chemical attributes [9]. The ability of PGMs to form
multiple coordination bonds with electron-rich atoms, such as nitrogen, oxygen, and sulfur, from
various ligands, allows for the incorporation of these metallic centres into known chemical scaffolds.
Consequently, PGM complexes are a diverse group of compounds, which can be easily fine-tuned,
resulting in widespread potential applications. These complexes have been the subject of much research
interest within fields of catalysis and biomedical applications, particularly cancer, having reported
many success stories [10,11]. Their biomedical applications, in particular, have been exhaustively
covered in the literature, with recent reviews comprehensively summarizing the biological activity
of PGMs, including their anticancer, antibacterial, and antiviral properties [12–15]. Selected PGM
compounds, like ruthenium complexes, are showing great promise as light-activated cytotoxic agents,
in the emerging field of photodynamic therapy, for cancer treatment [16,17].
Likewise, the introduction of PGM moieties into known pharmacological scaffolds, possessing
antiplasmodial activity, has been shown to enhance the biological activity of these organic compounds.
This approach offers an opportunity to restore the activity of antimalarial drugs, already suffering
full-blown clinical resistance, while displaying increased activity toward resistant P. falciparum
strains [18–20]. Most reviews covering the biological activity of PGM complexes, including malaria, have
predominantly focused on inorganic complexes, i.e., compounds with coordinate bonds between the
metal and a heteroatom. In this reference work, we highlight the antimalarial activity of organometallic
PGM complexes comprising at least one metal-carbon covalent bond, as well as their plausible/proposed
mechanisms of action, which have been documented in the literature. With respect to current trends in
research activities on PGM complexes, we have emphasized recent developments within this field
published over the past five years.
2. Iridium Complexes
Iridium complexes are among the most studied complexes for their biological activity, within the
PGM family of coordination compounds. Organometallic iridium compounds predominantly consist of
half-sandwich pentamethylcyclopentadienyl-coordinated chemical entities that adopt the well-known
three-legged piano-stool conformation. The investigation of iridium-based compounds, as antimalarial
agents, was brought into prominence by the seminal study of Navarro and colleagues in 2009, who
incorporated iridium into the scaffold of the quinolinyl clinical antimalarial drug, chloroquine (1, CQ),
to generate new antiplasmodial iridium complexes (2–4) [21]. These complexes displayed efficacy
comparable to the parental drug against a chemosensitive P. berghei malarial strain (Figure 1) [21].
Most notably, complex 2 demonstrated superior activity to chloroquine. Since then, iridium complexes
of non-chloroquine-based scaffolds, such as pyridyl esters (5) and salicylaldimine (6), have been
expansively studied for their inhibitory effects against both drug-resistant and -sensitive strains of the
Plasmodium parasite (Figure 1) [22,23].
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Figure 1. Chemical structures of chloroquine (1), the first antimalarial iridium-chloroquine complexes 
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retention within the active site of the parasite, i.e., digestive vacuole (DV), making this entity 
attractive to thwart the development of drug resistance [24]. 
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In 2016, Nordlander and co-workers investigated the antiplasmodial activity of N^N- and N^O-
coordinated IrCp* complexes, based on chloroquine analogues of salicylaldimine (7a–h), 2-
picolamine (8), and 2-aminomethylimidazole (9) as ligands (Figure 2) [24]. The uncoordinated 
ligands, as well as the corresponding complexes, were screened for their antiplasmodial activity 
against the chloroquine-sensitive (CQS) NF54 strain and the chloroquine -resistant (CQR) Dd2 strain 
of the malaria parasite, P. falciparum. Generally, the complexes exhibited activity in the sub-
micromolar range (0.030–0.677 μM), albeit lower than that of the corresponding ligands, with higher 
selectivity for the NF54 CQS strain. However, the majority of the tested complexes interestingly 
showed lower resistant indices (RI) compared with the ligands, which is a good indication of reduced 
cross-resistance upon complexation, with compounds 7e and 7g–h displaying increased efficacy 
against the chloroquine-resistant Dd2 (CQR) strain, compared with their corresponding ligands. 
Elucidation of the structure-activity relationship (SAR) analysis of the salicylaldiminato IrCp* 
complexes (7a–h) revealed no clear trend for the CQR strain, however, a linear correlation depicting 
an increase in activity upon substitution with electron-withdrawing groups (EWGs) was observed 
for the CQS strain. It should also be noted that the salicylaldimine ligand was more favorable for 
plasmodial potency, relative to the picolamine and imidazole ligands. A subsequent study, reported 
in the following year by the same research group, revealed that coordination with a pyrazine amide 
ligand (10) was detrimental for antiplasmodial activity, as the resulting complex was inactive at the 
highest tested concentration against the NF54 parasite strain (Figure 2) [25]. 
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The incorporation of the penta ethylcyclopentadienyl ( p*) ligand is favoured over the
unsubstituted cyclopentadienyl ( p) congener, o ing to its increased lipophilicity and higher
stability [24]. This enhanced stability is ascribed to the combined effects of steric shielding of
the metallic centre and the greater electron density within the Cp* ligand [24]. For chloroquine-derived
organo etallic iridiu co plexes, the enhanced lipophilicity of the p* ligand is hypothesized to
confer an overall i prove ent in the lipophilicity of the resultant co pound, leading to increased
retention ithin the active site of the parasite, i.e., digestive vacuole (DV), making this entity attractive
to thwart the development of drug resistance [24].
2.1. Quinoline-Salicylaldiminato/Picolamine/Imidazole Ligands
In 2016, Nordlander and co-workers investigated the antiplasmodial activity of NˆN- and
NˆO-coordinated IrCp* complexes, based on chloroquine analogues of salicylaldimine (7a–h),
2-picolamine (8), and 2-aminomethylimidazole (9) as ligands (Figure 2) [24]. The uncoordinated
ligands, as well as the corresponding complexes, were screened for their antiplasmodial activity
against the chloroquine-sensitive (CQS) NF54 strain and the chloroquine -resistant (CQR) Dd2
strain of the malaria parasite, P. falciparum. Generally, the complexes exhibited activity in the
sub-micromolar range (0.030–0.677 µM), albeit lower than that of the corresponding ligands, with
higher selectivity for the NF54 CQS strain. However, the majority of the tested complexes interestingly
showed lower resistant indices (RI) compared with the ligands, which is a good indication of reduced
cross-resistance upon complexation, with compounds 7e and 7g–h displaying increased efficacy against
the chloroquine-resistant Dd2 (CQR) strain, compared with their corresponding ligands. Elucidation
of the structure-activity relationship (SAR) analysis of the salicylaldiminato IrCp* complexes (7a–h)
revealed no clear trend for the CQR strain, however, a linear correlation depicting an increase in
activity upon substitution with electron-withdrawing groups (EWGs) was observed for the CQS strain.
It should also be noted that the salicylaldimine ligand was more favorable for plasmodial potency,
relative to the picolamine and imidazole ligands. A subsequent study, reported in the following year by
the same research group, revealed that coordination with a pyrazine amide ligand (10) was detrimental
for antiplasmodial activity, as the resulting complex was inactive at the highest tested concentration
against the NF54 parasite strain (Figure 2) [25].
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toward the CHO cell-line, and thus greater selectivity toward the malaria parasite, with selectivity 
indices greater than or equal to 10. The increased potency of the benzyl-PTA complexes (14–16) may 
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In another study, the Smith and Nordlander groups evaluated the antimalarial activity of
IrCp* complexes, based on the chloroquine nucleus, with NˆOˆP-coordination via salicylaldimine
and 1,3,5-triaza-phosphaadamantane (PTA) ligands (Figure 3) [26]. The incorporation of the
water-soluble PTA ligand was inspired by the medicinal attributes of this moiety, which was observed
within rutheniu (II)-arene PTA (RAPTA) co plexes, reported by the Dyson group, which showed
antiproliferative efficacy against several cancer cell-lines [27]. The ultiple basic nitrogen ato s
within the PTA unit increases the overall basicity of the resultant complex, providing multiple sites for
protonation once in the DV of the parasite, which is a feature crucial for the activity of anti alarial
drugs, particularly 4-a inoquinolines [28]. The PTA co plexes, isolated as hydrochloride salts,
displayed antiplas odial activity against CQS F54 and CQR K1 strains of P. falciparum, with IC50
values ranging bet een 0.11 and 1.7 µ [26]. The benzyl-PTA congeners (14–16) ere slightly ore
efficacious than their non-benzylated counterparts (11–13), against both parasite strains. Furthermore,
selected complexes (11, 12, and 15) were screened for their in vitro cytotoxicity against mammalian
Chinese hamster ovarian (CHO) cells. These complexes displayed reduced cytotoxicity toward the
CHO cell-line, and thus greater selectivity toward the malaria parasite, with selectivity indices greater
than or equal to 10. The increased potency of the benzyl-PTA complexes (14–16) may be rationalized
by their enhanced lipophilicity, owing to the presence of the benzyl unit. Mechanistic studies further
suggested that the complexes acted via the inhibition of hemozoin synthesis, which is a pathway
unique to the malaria parasite and a crucial detoxification mechanism.
2.2. Quinoline-Triazole Ligands
Melis et al. recently reported on a series of quinoline-triazole Ir(III)Cp* conjugates, shown to
inhibit the growth of NF54 and K1 strains of P. falciparum, with activities ranging between 0.25–2.34
µM and 0.65–3.06 µM, respectively (Figure 4) [29]. Most notably, the activities of the complexes
are substantially superior to those of the corresponding uncoordinated ligands, against the NF54
strain, with the activity, in some cases, exceeding that of the ligand by over 20-fold. This result
highlights the potential benefits of metal incorporation, within drug design, offering an opportunity
to enhance the pharmacological efficacy of organic compounds upon complexation. The cationic
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NˆN-coordinated pyridyl complex 18 was the most active in the series, against both the sensitive and
resistant strains, with IC50 values of 0.25 ± 0.11 and 0.63 ± 0.06 µM, respectively. Furthermore, the
selectivity indices for the tested complexes (17a–e, 18, and 20) suggest that they are not cytotoxic
toward the CHO-cell line, and thus display increased selectivity for the parasite, with complex 18
almost 500 times more selective toward parasitic cells than the mammalian cell-line. It was also noted
that the incorporation of hydrophobic substituents did not seem to influence the antiplasmodial activity
of the metal-based compounds. Furthermore, coordination at the quinoline nitrogen atom (19) was
found to be unfavourable for activity. Finally, preliminary mechanistic studies suggested a dual mode
of action by the compounds, involving inhibition of the hemozoin pathway and perturbation of the
NAD+/NADH biochemical process by intracellular catalysis, which will be discussed in Section 7.
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2.3. Sulfadoxine Ligands
Apart from the derivatization of chloroquine, appending IrCp* moieties to other known drug
scaffolds has proven to be a successful strategy to enhance the biological activity of the parental
organic compound, while imparting potentially new and beneficial pharmacological properties. Most
notably, complexation with the IrCp* moiety has been shown to restore the potency of antimalarial
drugs that have experienced total clinical resistance. Chellan and colleagues demonstrated this upon
their exploration of NˆN-chelated iridium analogues of the clinical antimalarial drug, sulfadoxine
(21), which is facing full resistance by P. falciparum strains (Figure 5) [30]. This group synthesized a
series of N,N′-chelate pyridylimino- (22) or quinolylimino- (23) IrCp* complexes, functionalized with
sulfadoxine (Figure 5), and evaluated their antiplasmodial activity against P. falciparum strains. The
complexes inhibited the growth of CQS (3D7 and late stage NF54 gametocytes) and CQR (Dd2) strains
of P. falciparum, with IC50 values in the sub- and low micromolar range, with no significant toxicity
towards non-pathogenic human embryonic kidney cells (HEK293). Annulation of the IrCp* moiety
with phenyl and biphenyl units was desirable for activity, as shown by the increased efficacy of the
complexes endowed with these rings, a fact that could be attributed to increased lipophilicity. This is
further corroborated by the superior activity of the bulkier isoquinolyl complexes (23a–c) compared
with their pyridyl congeners (22a–c). Most significantly, the parental drug sulfadoxine did not show
any toxicity toward the investigated P. falciparum strains, at the highest tested concentration, thus
illustrating the practicality of incorporating an IrCp* moiety into drug scaffolds as a viable approach
for restoring the activity of clinical drugs facing resistance.
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that substitution with CF3 is generally more tolerated for efficacy compared with other substituents.
Compound 25b, endowed with this substituent, possessed higher selectivity for the CQR strain over
the CQS strain, implying a higher resistance index. Furthermore, preliminary evaluation of the
compounds for their potential binding affinity to hematin, which is a common target for antimalarial
drugs, suggests a mechanistic modality independent of the hemozoin inhibition pathway.
Molecules 2020, 25, x FOR PEER REVIEW 7 of 32 
 
 
Figure 5. Chemical structures of IrCp* complexes based on the sulfadoxine scaffold and their 
corresponding IC50 values [30]. 
2.4. Benzimidazole (Hybrid) Ligands 
Recently, the research group of Smith reported a series of neutral, cyclometallated Ir(III)Cp* 
complexes (25), based on the 2-phenylbenzimidazole scaffold (24), showing in vitro antiplasmodial 
activity against NF54 and K1 strains of P. falciparum (Figure 6) [31]. The synthesized complexes 
displayed activities in the low micromolar range against the tested strains. Most noteworthy was the 
significant increase in activity observed upon metal complexation of the ligands (24a–d) with IrCp*, 
which enhanced the activity of ligands 24a–24c by 10- to 18-fold. Complexation of 24d, however, 
resulted in compound 25d being approximately 117 times more active than the uncoordinated ligand 
against the CQS NF54 strain, further highlighting the medicinal benefits of incorporating 
organometallic fragments into organic scaffolds. The complexes (25a–d), however, were less selective 
for the CQR K1 strain, as indicated by their lower activity. Evaluation of substituent effects on activity 
shows that substitution with CF3 is generally more tolerated for efficacy compared with other 
substituents. Compound 25b, endowed with this substituent, possessed higher selectivity for the 
CQR strain over the CQS strain, implying a higher resistance index. Furthermore, preliminary 
evaluation of the compounds for their potential binding affinity to hematin, which is a common target 
for antimalarial drugs, suggests a mechanistic modality independent of the hemozoin inhibition 
pathway. 
 
Figure 6. Chemical structures of antimalarial 2-phenylbenzimidazole ligands (24a–d) and their
corresponding IrCp* complexes (25a–d) as well as neutral and cationic quinolinyl-benzimidazole
hybrids (26–27) [31,32].
Encouraged by the promising biological performance of the 2-phenylbenzimidazole Ir(III)Cp*
complexes (25) against P. falciparum strains, a follow-up study entailed conjugation of a 4-aminoquinoline
motif to either 2-phenylbenzimidazole or 2-pyridylbenzimidazole, and subsequent complexation, to
yield neutral and cationic IrCp* and RhCp* complexes (Figure 6) [32]. The CˆN-coordinated neutral
complexes (26a–c) were more potent than their NˆN-complexed cationic counterparts (27a–c) against
both the K1 and NF54 strains of P. falciparum. Interestingly, the 2-phenylaminoquinoline-benzimidazole
hybrid complexes (26) showed an improvement in activity compared with their corresponding
2-phenylbenzimidazole congeners (25) against the CQR K1 strain. Moreover, only the Me- and
CF3-functionalized cationic derivatives (27b and 27c) were superior to their corresponding non-quinolyl
containing counterparts (25c and 25b) against the CQS NF54 strain [31,32]. Furthermore, the new
quinolinyl complexes demonstrated a significant binding affinity for synthetic hemozoin, β-hematin,
exceeding that of the positive control drug, CQ. These findings indicate that the introduction of the
pharmacophoric quinoline moiety is vital for antiplasmodial activity, as attested to by the results of
the biological assays and the remarkable hemozoin binding activity. Once again, the examination
of the substituent effects on activity revealed that CF3 enhances antiplasmodial efficacy. Finally, the
neutral CˆN-cyclometallated complexes (26), which displayed the most promising activity toward the
Plasmodium strains, revealed increased selectivity toward parasitic cells over the CHO mammalian
cells, with selectivity indices of >50 observed for complexes 26a and 26b.
3. Ruthenium Complexes
Ruthenium is one of the most versatile metals within the PGM block, with a myriad of applications
that span many industries, ranging from catalysis, solar energy technologies, cell-labelling utilities, and
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various therapeutic applications [33–37]. The success of ruthenium in catalysis is exemplified by the
epochal discovery of the Nobel Prize-winning Grubbs catalyst for olefin metathesis [33]. In the context
of biological applications, ruthenium complexes predominantly consist of η6-arene organometallic
fragments and have been exhaustively explored in the field of oncology, as anticancer agents, with
diverse modes of action. Evidence of the antimalarial activity of ruthenium-based compounds goes
as far back as 1996 and has been demonstrated by several research groups, upon complexation of
ruthenium to the chloroquine scaffold, which generated antiplasmodial agents with activity superior
to chloroquine, against both CQR and CQS P. falciparum strains (Figure 7, 28–31) [38–42]. Most notable
is the ruthenium analogue, 29a, of the ferrocenyl antimalarial clinical candidate ferroquine (29b). The
incorporation of a bis(η5-cyclopentadienyl)ruthenium motif (ruthenocene), in place of ferrocene, has
proven to be invaluable in unveiling the mode of action of ferroquine, in erythrocytes, owing to the
enhanced amenability of ruthenium for cell-labelling compared with iron [43].
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3.1. Tamoxifen Derivatives
Ru-arene complexes of bioactive motifs, such as thiosemicarbazones (TSCs), tetraoxanes, and
salicylaldimines, have been shown to possess antiplasmodial activity over the years. Krettli and
colleagues coordinated a ruthenocenyl entity into the scaffold of a tamoxifen-like compound (36),
which displays structural similarities to the anticancer drug, tamoxifen (32) [44]. By replacing ring B
with a ruthenocene entity, novel ruthenocenyl derivatives (33–35) were synthesized, which displayed
antiplasmodial activity against the CQR W2 strain of P. falciparum, with IC50 values between 5.9 and
16.5 µM (Figure 8) [44]. Most notably, the ruthenocenyl derivatives were superior in activity to the
parental organic ligand (36), which were shown to be inactive against the tested strain. This further
supports the potential of metal incorporation to not only improve the biological activity of bioactive
organic scaffolds, but also confer new biological activities.
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3.2. Quinoline-Salicylaldiminato/Imidazole Ligands
Ekengard et al. reported on a series of quinoline-based ruthenium complexes, endowed with
NˆO-salicylaldimine (37a–f) and NˆN-imidazolemethylamine (38) moieties [45]. These complexes were
shown to inhibit the growth of CQS NF54 and D10 as well as CQR Dd2 strains of P. falciparum, with
no indication of cross-resistance (Figure 9) [45]. SAR studies of the salicylaldimine complexes (37a–f)
revealed a trend between the substituents and the antiplasmodial activity. This study suggested that an
increase in the electron-withdrawing nature of the substituent, i.e., F > Cl > Br > I and OMe > H > NO2
> But, resulted in an increase in the potency of the resultant complex. Furthermore, the replacement of
salicylaldimine with a 2-imidazolemethylamine ligand (38) led to a drastic decrease in activity, by 8- to
10-fold. Intriguingly, the activity against both strains was significantly augmented upon complexation
of the Ru(II)(p-cymene)Cl2 motif to the quinoline nitrogen atom (39).Molecules 2020, 25, x FOR PEER REVIEW 10 of 32 
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3.3. Thiosemicarbazone and Organosilane Derivatives
Heteronuclear Ru(II)(p-cymene) complexes, containing ferrocenyl (40a,b) and 3,4-dichlorophenyl
(41a–c) bioisosteric units, based on an N-terminated organosilane TSC backbone, have also been
reported (Figure 10) [46]. The appeal of ruthenium-based TSC complexes (42–43), as promising
antiplasmodial agents, has been previously established by Adams et al. against CQS NF54 and CQR
Dd2 strains of P. falciparum [47]. Within this study, the chloro-aryl thiosemicarbazones (42a,b) emerged
as the most potent in the series [47]. In other studies, an organosilane moiety was incorporated into the
lateral alkyl side chain of chloroquine- and ferroquine-derived ruthenium complexes, leading to the
attainment of highly potent antimalarial agents (44–45), active in the low nanomolar range, targeting
the malarial hemozoin pathway [48,49]. Organosilane moieties are famous for their exceptional
lipophilic properties and have been incorporated into privileged drug scaffolds, to augment their
biological activities and impart new therapeutic benefits [50,51]. This has been successfully applied
in drug discovery to increase the cell permeability of drug molecules and, consequently, their tissue
penetrating ability and thus bioavailability [52,53]. It should also be noted that all the silicon-containing
aminoquinoline complexes (44) displayed lower resistance indices than CQ, with complexes 44d
and 44e showing activity greater than CQ against the Dd2 strain of the parasite P. falciparum [48].
Furthermore, all of the ferroquine-derived counterparts (45a–c) were shown to be approximately
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2.5-fold more potent than CQ against the Dd2 strain, and up to 8.5-fold more potent than ferroquine
against the NF54 strain [49]. These observations were an unequivocal indication that the presence of
the terminally appended organosilane motif had a significant impact on the antiplasmodial activity.
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Premised on the promising antimalarial activity of Ru-TSC complexes and the beneficial
organosilane motif, S ith and col eagues rational y co bined TSC and organosilane moieties to
produce NˆS-chelated silyl TSC Ru(II) complexes 40–41 [46]. Despite the complexes showing high
selectivity for the malaria parasites over the mammalian CHO cel s, no significant improvement in
activity was noticed upon complexation of the cor esponding fer ocenyl and phenyl TSC ligands, as
the resulting Ru(II) complexes exhibited lower, albeit comparable, toxicity the ligands. An exception
to this was the non-silyl 3,4-dichlorophenyl representativ complex 41c, which was 68 times more
active than its respective ligand against the CQS NF54 strain. On a positive note, these new silyl
complexes were significantly more active than their related non-silyl a alogues (42–43) that had been
reported earlier [47]. Aga n, this was further confirmation of the pharmacological importan e of the
organosilane moiety appended to the side chain of the TSC stru tural motif, as previously shown for
chloroq ine and ferr quine Ru(II) complexes [48,49]. Table 1 lists the IC50 values of complexes 40–45
against the CQS NF5 and CQR K1 strains of P. falciparum, along with the resist nce and selectivity
indices for select d ompounds [46–49].
Molecules 2020, 25, 5276 11 of 31
Table 1. Antimalarial activity of Ru(II)-based thiosemicarbazone (TSC) (40–43) and quinoline (44–45)




RI b SI c
NF54 Dd2 CHO
40b 7.81 ± 0.56 – d – – –
41a 2.92 ± 0.33 4.28 ± 0.33 71.8 ± 8.11 1.47 24.6
41b 4.19 ± 0.12 6.66 ± 2.58 21.5 ± 0.80 1.59 5.14
41c 2.57 ± 0.99 2.29 ± 0.25 3.65 ± 0.630 0.89 1.42
42a 6.20 ± 1.00 – – – –
42b 2.90 ± 0.90 3.8 ± 0.2 – – –
43a 16.5 ± 1.00 14.1 ± 0.90 – – –
43b 8.60 ± 0.60 6.60 ± 0.30 – – –
44a 276.8 ± 31.0 526.56 ± 70.85 – 1.90 –
44b 61.4 ± 10.3 >1749 – >28.5 –
44c 270.2 ± 35.9 835.09 ± 190.03 – 3.09 –
44d 81.6 ± 7.40 228.96 ± 4.06 – 2.81 –
44e 71.7 ± 4.80 211.77 ± 22.68 – 2.95 –
44f 151.9 ± 14.1 385.61 ± 8.48 – 2.54 –
45a 8.27 ± 0.38 42.73 ± 12.78 – 5.17 –
45b 30.7 ± 2.70 42.99 ± 1.08 – 1.40 –
45c 4.96 ± 0.76 36.64 ± 4.33 – 7.39 –
CQ 5.43 ± 2.13 108.36 ± 1.10 – 19.95 –
FQ 42.6 ± 9.91 27.67 ± 6.46 – 0.65 –
IC50 (µM) a = half-maximal inhibitory concentration; activity for 44–45, chloroquine (CQ), and Ferroquine (FQ) is
reported in nM. RI b = resistance index, ratio of Dd2 IC50 to NF54 IC50. SI c = selectivity index, ratio of CHO IC50 to
NF54 IC50. CHO = Chinese hamster ovarian. d Not determined. Data adapted from references [46–49].
3.4. Quinoline-Trioxane Ligands
In 2016, Martinez and colleagues ingeniously amalgamated two antimalarial pharmacophoric
entities, 4-aminoquinoline present in chloroquine (CQ) and 1,2,4-triaoxane of artemisinin (46), together
with ruthenocene, culminating in a novel ruthenium-based antimalarial agent (47) endowed with
three moieties that are vital for antimalarial activity (Figure 11) [54]. The resulting organo-ruthenium
aminoquinoline-trioxane hybrid (47) was highly potent against CQR K1 (16.96 ± 2.93 nM) and Dd2
(51.16 ± 10.39 nM) strains, with >7-fold improvement in activity relative to CQ. Interestingly, this
compound showed high selectivity for the parasitic strains over the healthy human MRC5 cells
translating into marked selectivity indices of 92 and 30 for the K1 and Dd2 P. falciparum strains,
respectively. The impressive efficacy of 47 was comparable to that of the other potent organometallic
antimalarial compounds, such as ferroquine, ruthenoquine, and trioxaferroquine, poised to overcome
clinical resistance by CQR P. falciparum strains. Preliminary SAR interrogation of the hybrid revealed
that the 4-aminoquinoline nucleus is critical for activity as the non-quinoline ruthenocene-trioxane
analogue 48 exhibited inferior activity to hybrid 47. Moreover, the plain trioxane substrate (46) had even
more diminished activity, thus underscoring the pharmacological importance of the ruthenocene unit.
3.5. Heteroaromatic Ligands
Patel et al. conjugated Ru(III)Cp* to a selection of planar polycyclic heteroaromatic ligands with
structural conformations desirable for DNA binding, in order to target resistant clinical isolates of the
P. falciparum parasite, as well as fungal (S. bombe) and bacterial pathogens (S. Aureus, S. marcescens, B.
subtilis, P. aeruginosa, and E. coli) [55,56]. The first cohort of complexes (Figure 12) was assembled from
a modified 4-arylquinoline moiety grafted with heteroaryl ring units, i.e., 2-pyridine and 2-thiophene,
at C2 to produce NˆN- and NˆS-coordinated Ru(III)Cp* complexes (49a–d and 50a–c), respectively [55].
All the complexes showed activities below 1.0 mg/mL with higher potency being observed for the
NˆN-chelated pyridyl congeners (49a–d) over the thiophenyl counterparts (50a–c). On the other hand,
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the antiplasmodial effects of the corresponding uncomplexed ligands were inferior (around 1.6 mg/mL),
once again stressing the medicinal benefits of incorporating metallic complexes into bioactive scaffolds
as a viable avenue to improve their antimalarial activity. Preliminary toxicity assessments of the
compounds in brine shrimp indicated strong cytotoxicity of complexes, which could be interpreted as
a promising indication of their antiproliferative potential as anticancer agents.
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( or RNA) through a different mechanism, leading to the disruption of several es ntial biologic l
pr cesses vital for the survival of the targeted pathogen, which subsequently induces cel death [57,58].
Consequently, elucidatio of a probable mechanism of action of the complexes (49–50) was carried out
on herring sperm DNA (HS-DNA) using various biochemical protocols: UV/vis tit a ion, viscosity
(or hydrodynamic volume) measurements, agarose g l electrophoresis (AGE), and in lico docki g
simulations [55]. The authors demonstrated that the complexes exhibit strong DNA-binding affinity
via intercalation with binding constants in the range 0.30 × 105–6.25 × 105 L/mol. Intriguingly,
compound 49c, which emerged as the most toxic candidate against P. falciparum parasitaemia in the
study, displayed the highest affinity for HS-DNA, thus suggesting a correlation between activity and
DNA interaction. The second cohort of polycyclic [Ru(III)ClCp*] complexes, featuring tri-arylated
pyrazoline ligands (51a–g), was also active against the clinical isolates in the IC50 range of 0.54–2.15
mg/mL, with compound 51a exhibiting the highest activity [56]. The complexes interacted with DNA
Molecules 2020, 25, 5276 13 of 31
in a similar manner to the quinolinyl complexes 50–51 and the binding constants were in the same
order of magnitude.
3.6. Quinoline/Benzimidazole Ligands
A study by Stringer et al. included quinolinyl RAPTAs 52–53 showing inhibitory activity on the
growth of CQS NF54 and CQR K1 P. falciparum strains at half-maximal concentrations in the ranges of
0.10–0.40 and 1.6–4.5 µM, respectively (Figure 13) [26]. Generally, incorporation of the PTA moiety
by coordination to the metallic centre of the Ru(II)(p-cymene) unit augmented the activity of the
complexes against the sensitive strain for the same reasons discussed earlier for the Ir(III)Cp* congeners.
High selectivity indices of >10 were observed for the malaria parasites over the mammalian cells for
selected promising complexes tested on CHO cells. Antiplasmodial activity of neutral Ru(II)(p-cymene)
derivatives 54a–d (Figure 13), of the 2-phenylbenzimidazole PGM complexes, was also reported in
the same range as their Ir(III)Cp* congeners 25a–d (Figure 6) discussed earlier [31]. Likewise, the
activity of these complexes was superior to the uncomplexed ligands 24a–d (Figure 6), emphasizing
the significance of the presence of the organometallic Ru(II)(p-cymene) unit.
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4. Rhodium Complexes
The application of rhodium complexes, especially the forms with the 3+ oxidation state, i.e.,
Rh(III), for biological evaluation has often been overlooked because of the perception that they may
show limited biological activity owing to their inert chemical nature [59]. However, recently, rhodium
complexes have been increasingly gaining favour among medicinal organometallic chemists to expand
the antimalarial drug arsenal and potentially diversify the mechanisms of action. An early example of
an antimalarial rhodium complex is the Rh(I)-CQ conjugate of 2 (Figure 1) formed by coordination
of a RhCl(COD) unit (COD = 1,5-cyclooctodiene) via the N1 atom of the quinoline nucleus, which
demonstrated enhanced activity compared with the control drug in vivo, in mice infected with P.
berghei parasitemia [38].
4.1. Salicylaldiminato Ligands
A series of heteronuclear ferrocenyl azine complexes 55a–c was endowed with the organometallic
Rh(I)COD motif via bidentate NˆO-coordination, which was active against CQS NF54 and CQR K1
P. falciparum strains (Figure 14) [60]. The complexes showed antiplasmodial activities in the low
micromolar range against both strains and low resistance indices for 55b–c (RI = 0.22–0.85). The
uncomplexed ferrocenyl azine ligands 56a–c were less potent, signifying the favourable pharmacological
effects of introducing the organometallic Rh(I)COD unit. Mechanistic examination using the
NP40-mediated β-hematin assay suggests disruption of the heme detoxification pathway as a possible
mode of action. Before these studies, Rh(I)ClCp* congeners 57a and 58a exhibiting reversible redox
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character were investigated for their antiplasmodial effects on the CQS NF54 parasites along with their
Ir(III)ClCp* (57b and 58b) and Ru(II)Cl(p-cymene) (57c and 58c) derivatives [23,61]. In both studies,
the Rh(I)ClCp* complexes displayed comparable activities to the Ir(III)ClCp* and Ru(II)(p-cymene)
derivatives, placing the rhodium metal as an attractive alternative to the extensively studied iridium
and ruthenium metals for the generation of bioactive organometallic compounds. Again, the bimetallic
complexes were significantly superior in activity to their respective ferrocenyl ligands. Introducing
aqueous solubility to complexes 58a–c, by incorporation of a water-soluble sulfonate group at position
C5 of the benzene ring, led to a decrease in the activity of the complexes, and no discernible β-hematin
binding affinity was observed at the maximum tested concentration (IC50 > 100 µM). The latter
observation would seem to suggest that the observed inhibitory action of the water-soluble sulfonate
compounds on the screened strain proceeds via alternative modes of action such as the generation of
reactive-oxygen species (ROS) in which the ferrocene unit plays a pivotal role by undergoing reversible
Fenton-type redox processes inside the DV of the malaria parasite [62,63].
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4.2. Quinoline-Salicylaldiminato and Sulfadoxine Ligands
In addition to the bidentate chloroquine-derived Nˆ - and Nˆ -chelated Ir(III)ClCp* co plexes
7–10 (Figure 2), ordlander and colleagues reported the antiplas odial activity of Rh(III)ClCp*
congeners 59–62 exhibiting activity against CQS NF54 and CQR Dd2 P. falciparum strain
(Figure 15) [24,25]. These rhodium complexes were more active than their Ir(III)ClCp* variants 7–10 in
the sub-micromolar range (IC50: 0.16–0.209 µM) against the sensitive strain, although less active against
the resistant strain (0.20–0.40 µM). Interrogation of complexation effects and influence of substitution
effects on the benzene ring revealed similar SAR trends as the iridium derivatives (7–10) previously
discussed. Likewise, Chellan et al. also studied the antiplasmodial potency of the rhodium(III)
counterparts (63–64) of the organometallic iridium(III) pyridyl- and isoquinolyl-sulfadoxine conjugates
(22–23, Figure 5) against CQS 3D7 and NF54 strains, as well as resistant Dd2 parasites, which generally
displayed a significant improvement in activity relative to the Ir(III) complexes across all strains
(Figure 15) [30]. Again, the generated SAR trends were similar for both types of complexes, as
discussed earlier. The results from the studies by these research groups seem to suggest that the
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oxidation state of the metallic centre is critical in regulating the activity of the rhodium complexes;
particularly, the 3+ oxidation state of the rhodium metal confers overall favourable antimalarial activity
to the resultant organometallic agents, while the 1+ state is less favourable.
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4.3. Thiosemicarbazone and Benzimidazole (Hybrid) Ligands
Rh(III)Cl p* silyl congeners (65–66) of Ru(II)(p-cymene) ferrocenyl and 3,4-dichlorophenyl TSC
complexes (40–41, Figure 10) were also screened for their antimalarial potential against CQS F45
and CQR Dd2 parasitemia in vitro, with the majority exhibiting better activity compared with the
ruthenium(II) analogues (Figure 16) [46]. The activity of the Rh(III) compounds was correlated to
their β-hematin inhibition activity. Intriguingly, the carbosilane complex 66b was the most active
in the series and exhibited better β-hematin activity than the control drug, chloroquine. This could
be explained by the high lipophilic character of the silyl motif, which might enhance the binding
interactions of 66b to the growing hemozoin polymer chain. Also noteworthy were the minimal
instances of cross resistance and general toxicity observed for these complexes, as indicated by their
low resistance indices when comparing activities on both strains and high selectivity indices on the
mammalian CHO cell line. Similarly, Rh(III)ClCp* benzimidazole complexes (67) inhibited the growth
of sensitive strains of P. falciparum, albeit less effective than the Ru(II)Cl(p-cymene) (54, Figure 13) and
Ir(III)ClCp* (25, Figure 6) derivatives [31]. Conjugation of these complexes to the 4-aminoquinoline
nucleus significantly enhanced the activity of the compounds (68–69), making them more potent
than the Ir(III) congeners with higher selectivity towards the malaria parasites (NF54 and K1) over
the mammalian CHO cells (SI > 20) [32]. Collectively, data from these studies seem to reinforce the
previous observation regarding the beneficial pharmacological effects of the +3 oxidation state on the
antiplasmodial activity of Rh(III) complexes.
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complexes into known drug scaffolds as a viable approach to modulate their activity.
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choice of coordinating and ancillary ligands allows further tuning of photophysical properties and
confers three-dimensional spatial configuration to the complex, which offers better recognition and
guest–host interaction with biological receptors [67]. As a result, osmium complexes have become
versatile with great promise for utility in cancer treatment, including light-activated cancer therapy and
photodynamic therapy [68,69]. The anticancer effects of osmium complexes are succinctly discussed
in the reviews by Hanif et al. [70], Meier-Menches et al. [71], and Nabiyeva et al. [72]. Examples of
osmium complexes that demonstrate antiproliferative effects include the Os(II/III) analogues (72) of
the well-studied Ru(II/III) RAPTA complexes shown in Figure 18 [72].
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Quinoline-Salicylaldiminato/Imidazole Ligands
Despite the demonstrable biological poten ial of osmium complexes, antimalarial investigation of
osmium co plexes is limited n the litera ure. To date, only one study investigating the antimalarial
activ ty of osmium complexes is known. In this report, Nordlander and colleagues v luated Os(II)
analogues (73–75) of Ru(II)Cl(p-cymene) complexes 37–39 (Figure 9) in vitro on sensitive (NF54 and
D10) and resistant (Dd2) P. f lciparum strains for antiplasmodial activity (Figure 19) [45]. The activity
of the complexes 73–75 was comparable to the Ru(II) analogues 37–39 on all tested strains. In a few
cases, the Os(II) complexes were more potent than their Ru(II) count rparts, signifying the attractive
antimalarial potential of osmium-b sed compounds. Given these observations, it is appar t that
osmium complexe re worthy of further consideration in the context of their antim larial activity.
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6. Platinum and Palladium Complexes
Platinum is the pioneering metal in the interest of PGM complexes as biological agents for targeting
diseases. The activity of platinum complexes goes as far back as the 1960s with the epochal discovery
of the anticancer activity of cis-diamminedichloridoplatinum(II), commonly known as cisplatin, by
Rosenberg and co-workers [73]. Next generation platinum(II) derivatives (77–79), shown in Figure 20,
have since been developed and approved to address the challenges faced by cisplatin (76), namely,
limited selectivity, development of clinical resistance, and acute toxicity [74,75].
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Thiosemicarbazone Ligands
Chellan et al. synthesized tridentate CˆNˆS cycloplatinated TSC complexes with antiplasmodial
activity against CQS D10 and CQR Dd2 strains as well as antiproliferative and antitrichomonal effects
on ovarian cell lines and Trichomonas vaginalis parasites (Figure 21) [80]. Cycloplatination was achieved
via C-H activation of the TSC ligand to generate a tetrameric complex (82) with platinum-sulfur bridges.
Ligation of this tetramer with mono- and bi-phoshino ligands (triphenylphosphine (PPh3), PTA, and
bis(diphenylphosphino)ferrocene and trans-bis(diphenylphosphino)ethylene, respectively) led to the
attainment of the corresponding mono- and binuclear cycloplatinated TSC products (83a,b and 84a,b).
Pharmacological screening of complexes for their antiplasmodial effects in vitro revealed that only
the tetra- and mononuclear complexes (82 and 83a,b) were active against the plasmodial parasites,
with IC50 activities between 19.93 and 32.92 µM, whereas the binuclear equivalents 84a,b endowed
with bis-phosphino ligands were impotent. Intriguingly, compound 83a ligated with PPh3 showed
no indication of cross-resistance, as attested by its higher selectivity towards the resistant Dd2 strain
(14.47 ± 1.98 µM) over the chemosensitive D10 variant (19.93 ± 3.74 µM). The PTA analogue similarly
showed minimal effects of cross-resistance because activities on both strains were almost equivalent
(21.42 ± 1.22 µM vs. 24.90 ± 3.24 µM).
On the other hand, organometallic complexes of the related congener metal, palladium, are more
prevalent in the literature. The coordination chemistry of palladium complexes closely resembles
their platinum counterparts more than any other metals within the PGM block [81,82]. Moreover, the
faster ligand-exchange and aquation rates (more than 105 times) of palladium complexes lead to higher
solubility relative to their platinum congeners, making them attractive for application in biological
systems [83,84]. Hence, interest in their biological potential is only logical considering the success
of the structurally similar platinum complexes in anticancer treatment. Consequently, there have
been various studies on the biological activity of palladium complexes since Graham and Williams
proposed the investigation of palladium complexes as anti-infective agents and promising anticancer
alternatives to platinum in their pioneering studies [85]. Like in cancer, palladium complexes in
malaria research have been explored in the literature with a fair representation of cyclopalladated
organometallic variants [86–91].
Organometallic mono-, di-, and tetranuclear CˆNˆS-coordinated Pd(II) complexes based on the
TSC scaffold were synthesized and studied for their antiplasmodial activity against CQS 3D7 and
CQR K1 P. falciparum strains to ascertain the influence of coordination with palladium and the effects
of having multiple metallic centres on the activity of the ligands [88]. Tetranuclear complexes 85a,b
were assembled by coordination of previously tested antiplasmodial TSC ligands with potassium
tetrachloropalladate(II), forming a product with a Pd4S4 core due to the palladium-sulfur bridging
bonds (Figure 22). Cleavage of the Pd4S4 bridges in these complexes with PPh3 and diphosphino
ligands yielded mono- and binuclear cyclopalladated complexes (86a,b and 87), respectively. The
biological assessment of the obtained compounds revealed that incorporation of the Pd(II) centre
increased the inhibitory activity of the complexes as the tetranuclear (85a,b) and mononuclear (86a,b)
compounds were more potent than their respective TSC ligands against CQS 3D7 and CQR K1
strains, with IC50 values below 6 µM. The mononuclear complexes emerged as the most active
in the study particularly against the sensitive strain, suggesting the presence of multiple Pd(II)
centres had no marked effects on biological activity. Intriguingly, only the complexes containing the
1,1’-bis(diphenylphosphino)ferrocene linkage (87a and 88a) were active, while the non-ferrocenyl
ethylene and benzene counterparts were inactive within the binuclear series. This highlights the
beneficial pharmacological effects of ferrocene [63].
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activity of the complexes by an average of ~31-fold relative to the uncoordinated ligands on the NF54
and Dd2 strains. Ferrocenyl complexes 93a,b active between 1.07 and 1.52 µM were less potent than the
dichlorobenzene derivatives, which exhibited activities mainly in the sub-micromolar range (0.29–0.88
µM) against both strains. Most noteworthy, these complexes showed a great improvement in activity
compared with the variants devoid of the one- and two-carbon linkers on the terminal carbon from
the previous study (88a,b), which were only active at 1.73–2.69 µM on the same parasites. To further
illustrate the pharmacological significance of the organosilane moiety, when the authors compared the
effectiveness of the silyl complexes (92a,b) to their carbon analogues (91a,b), the activity was found to
be twice as good with preferential activity towards the resistant strain (Dd2). It is clear from these
observations that the incorporation of the organosilane moiety is a practical approach to enhance the
therapeutic efficacy of antiplasmodial agents, as also observed elsewhere in other studies.
7. Insights into Antiplasmodial Mechanisms of Action of Organometallic PGM Complexes
Extensive studies have been directed towards evaluating the inhibitory activity of PGM-derived
organometallic complexes as potential antimalarial agents against a myriad of P. falciparum strains.
The same could be said for anticancer research, which has by far received much greater attention than
antimalarial research. To this end, there has been a hive of activity among bioorganometallic chemists
not only to demonstrate the biological activity of such complexes with cell-based assays, but also in an
attempt to elucidate their possible modes of action by which they may exhibit activity. This is a crucial
step in the early stages of the drug development pipeline and raises the chances of a drug candidate
making it through the clinical assessment phases. For instance, the mode of action of anticancer
complexes such as cisplatin and related analogues has been established through thorough mechanistic
investigations [92,93]. However, the same cannot be said for a majority of antimalarial organometallic
complexes. In this section, we draw attention to the literature reports of this sparsely-researched field
and the available data on the investigation of possible mechanistic modalities of organometallic PGM
complexes and potential opportunities for further exploration of such targets. Mechanistic insights into
the antimalarial organometallic complexes have primarily focused on three targets, namely, hemozoin
inhibition (a mainstay for quinoline antimalarials); interaction with nucleic acids, particularly DNA;
and intracellular catalysis. These are discussed below.
7.1. Blocking the Plasmodial Heme Biocrystallisation Pathway
During the blood stages of the malaria parasite’s lifecycle, the Plasmodium species digests
haemoglobin from the human host to support its metabolic requirements and for sustenance [94]. The
process leads to the concomitant formation of free haem molecules that are toxic to the parasite through
the production of reactive oxygen species, leading to its death. To counteract this effect, the malaria
parasite has developed a pathway that biocrystallizes free heme molecules into insoluble, non-toxic
crystalline hemozoin, also known as the malaria pigment. This takes place inside the parasite’s acidic
DV (pH 5.2–5.6). Traditional antimalarial drugs, most notably quinolines, have been proposed to induce
antimalarial activity by blocking this pathway via binding interaction with heme [95,96]. For instance,
chloroquine accumulates in the plasmodial DV and binds to polymerizing heme complexes to halt the
biocrystallization process, thereby liberating more heme molecules to kill the parasite [96]. It is on this
premise that this pathway has been a subject of widespread research interest to devise novel bioactive
compounds for antimalarial activity through its blockade. Organometallic complexes of transition
metals, such as ferroquine, have been successfully applied to target heme detoxification [97,98]. Apart
from this, several organometallic complexes show reversible redox character capable of generating ROS
due to the presence of the metallic centre and can also introduce new therapeutic benefits, including
high lipophilicity and improved cell membrane permeability [99].
Several antiplasmodial PGM organometallic complexes have been explored for the inhibition of
the hemozoin pathway with selected iridium [26,29,32], ruthenium [46,48,49], and rhodium [32,46,60]
complexes already discussed in this review showing positive inhibitory activity. These were investigated
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employing the detergent-mediatedβ-hematin bioassay developed by Ncokazi and Egan, an invaluable tool
in detecting and measuring inhibition of the plasmodial heme biocrystallization process by antimalarial
agents [100]. Although many complexes evaluated for the blockade of this pathway were less potent
than the clinical antimalarial drug, chloroquine, their β-hematin inhibition activity was in agreement with
their antiplasmodial effects against the tested P. falciparum strains in most cases. Interestingly, compounds
containing the organosilane moiety in their scaffolds such as the Rh(III)Cp* TSC, 66b, as well as ferroquine-
and chloroquine-derived Ru(II), Rh(II), and Rh(I) complexes, were superior hemozoin inhibitors to the
control drug (CQ) [46,48,49]. However, a direct correlation between antiplasmodial activity and hemozoin
inhibition could be discerned for the quinolinyl complexes [48,49].
7.2. Targeting DNA Interaction for Antiplasmodial Activity
DNA is integral in an array of biochemical processes, from the coding of genes necessary for
regulation of normal cellular functions to the expression of proteins that are pivotal in the pathology of
diseases. Considering the substantial variations between human and plasmodial genomes, particularly
nucleotide base composition, it is possible and sensible to devise chemical agents that target the
malarial parasites over normal human cells by exploiting these differences. Most noteworthy in
these variations is the abnormal adenosine- and thymine-rich content in the DNA of Plasmodium
parasites [101,102]. This alteration affects the structure of plasmodial DNA and potential binding sites
for external compounds, offering medicinal chemists an opportunity to formulate chemotypes that can
selectively target these sites to inhibit the growth of P. falciparum parasites, as has been demonstrated in
the literature [102–104]. Ruthenium organometallic complexes have been tested for DNA interaction
as a possible mechanism of action for inducing antiparasitic effects.
The Ru(III)Cp* complexes 49–51 (Figure 12) reported by Patel and associates were also investigated
for DNA interaction using HS-DNA, as previously discussed [55,56]. Ruthenium(III) complexes are
touted for their impressive DNA binding affinity as possible chemotherapeutic agents, and this has
been extensively studied in cancer research of bioorganometallic complexes [105–108]. The binding
affinity of the complexes, quantified in terms of binding constants, agreed with their observed in vitro
antiplasmodial activity assessed in P. falciparum clinical isolates. This relationship is illustrated in
Figure 24A, showing a plot of DNA binding constants as a function of the antiplasmodial activity.
As can be seen in the figure, compounds’ low IC50 values translate to high DNA binding affinity in
a nearly linear relationship. The bathochromic spectral shifts (∆λ = 2–4 nm) observed in the UV/vis
DNA titration curves, shown in Figure 24B for complex 49c, suggested stacking interactions of the
complexes with DNA base pairs, i.e., DNA intercalation, which was confirmed by DNA viscosity
measurements and in silico docking simulations.
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Agarose gel electrophoresis (AGE) experiments suggested the complexes were also capable
of inducing cleavage of supercoiled pUC19 plasmid DNA by hydrolytic or oxidative processes.
Additionally, the computational docking simulation studies with selected candidates revealed that the
complexes elicit preferential binding to AT-rich regions of the model DNA structure used as a receptor
via van der Waals interactions. This finding demonstrates the practicality of targeting plasmodial DNA
over the DNA of the human host for the generation of organometallic chemotypes with good selectivity
towards the malaria parasites. To further illustrate this point, the authors tested the complexes for
general toxicity effects in a brine shrimp model, an inexpensive first-line measure for screening the
lethality of antiparasitic compounds, which could be attributed to the complexes having selective
binding affinity for plasmodial DNA. The complexes exhibited higher inhibitory potency in the P.
falciparum parasites vis-à-vis the brine shrimp, indicating high selectivity indices of the compounds
for malaria.
7.3. Disruption of Plasmodial Biochemical Processes by Intracellular Catalysis
Transition metals are renowned for their catalytic activity in many chemical transformations.
Similar chemical transformations and analogous processes effected by these metals such as transfer
hydrogenation, oxidation, and reduction are known to also occur in biological systems where they are
mediated by enzymes. It is no surprise that, in recent years, transition metals have begun to be explored
for catalysis of chemical processes in biological systems [109–111]. This has inspired medicinal and
bioinorganic chemists to devise innovative metal-based compounds capable of acting as intracellular
catalysts in relevant biochemical processes that are pivotal in the normal functioning of pathogenic
cells or organisms, hopefully leading to their disruption and eventual cell death to produce therapeutic
effects [109–111]. Considering that many clinical drugs react in stoichiometric equivalents with their
biomolecular targets, which may require high dosages to deliver desired therapeutic efficacy and
potentially lead to severe side effects, the intracellular catalysis strategy offers many advantages because
only small quantities of the catalytic metallodrug would be needed to attain the same therapeutic effect,
thus translating to lower drug dosages and minimal side effects [111]. This approach is increasingly
gaining attention in contemporary drug discovery and is showing encouraging results in cancer
research [112–115]. In particular, examples of PGM complexes bearing ruthenium, osmium, and
rhodium metallic centres have been demonstrated to catalyse transfer hydrogenation associated with
their antiproliferative activity [112–115].
In malaria research, targeting biochemical processes by intracellular catalysis is still nascent.
However, there are representative PGM complexes in the literature, some of which are discussed in
this review, reported to catalyse the transformation of biomolecules such as NAD+ and NADH, in
an attempt to demonstrate their ability to perturb the associated biochemical process as a possible
antiplasmodial mode of action. Studies by Melis et al. [29] and Stringer et al. [116] investigated
the ability of quinolinyl Ir(III)Cp* and Rh(II)Cp* complexes to disrupt the transfer hydrogenation
cycle of enzyme cofactors NAD+/NADH, a crucial biochemical process, via intracellular catalysis as a
possible mechanistic modality to explain their antiplasmodial activity. The assay employed to realise
this study is based on the principle of the Plasmodium lactate dehydrogenase (pLDH) method first
reported by Makler and associates, which has become a mainstay for detecting the antiplasmodial
activity of bioactive compounds in vitro [117]. In this protocol, NADH is utilised by pLDH to produce
pyruvate from lactate while simultaneously reducing co-factor APAP+ into APAPH, which can convert
a tetrazolium dye to blue formazan, thereby allowing monitoring of pLDH activity and growth of
parasitaemia, as the two are closely linked. NADH can also reduce a tetrazolium dye to blue formazan
in a similar manner to APAPH. In the modified procedure for detecting potential intracellular catalysis
of the complexes, transformation of NADH to NAD+ in the presence of a catalytic PGM complex
(and sodium formate as hydride source) was detected by following the absorbance of blue formazan
formed from yellow tetrazolium dye in the reduction process (Figure 25). In all cases, the formation of
blue formazan was detected, and the measured absorbance was proportionate to the concentration
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of complexes, suggesting positive catalysis of the NAD+/NADH transfer hydrogenation cycle by
the complexes.
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chemosensitive and drug resistant strains of the P. falciparum parasite. Incorporation of PGM centres
into bioactive ligands enhances their antiplasmodial activity, often with minimal toxicity towards
mammalian cells. Remarkably, some PGM complexes do not seem to exhibit cross-resistance in in vitro
biological assessment assays, a feat that can be attributed to the presence of metallic centres. While the
antiplasmodial activity of most PGM complexes is well-documented in the literature, we also note
that there is a great explorative scope regarding the antimalarial activity of organometallic osmium
complexes as well as cyclometallated platinum compounds. Like many antimalarial compounds,
PGM complexes also possess the ability to disrupt the heme detoxification pathway of the malaria
parasite as a mode of action, although this property may be primarily dependent on the nature of
the coordinating ligand. The affinity of PGMs for coordinating biomolecules is also illustrated by the
Ru(III)Cp* complexes that interact with DNA to induce plasmodial efficacy. The suggested mode of
DNA-binding involving stacking interactions with the AT-rich regions unique to plasmodial DNA
could allow more specificity for targeting P. falciparum over the human host, paving a way for the
design of PGM complexes with enhanced efficacy and lower toxicity to human cells. Application of
PGM-based compounds, specifically iridium and rhodium complexes, as NAD+/NADH hydrogen
transfer catalysts highlights the practicality of this approach not only as a novel mechanistic modality in
malaria, but also as a viable avenue for lowering the effects of toxicity of antimalarial PGM metallodrugs
while retaining the desired therapeutic benefit.
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